Extract

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i) peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary hypertension after pulmonary endarterectomy.

Inclusion criteria

• Chronic Thromboembolic Pulmonary Hypertension

Country

• Australia
• Austria
• Belgium
• Canada
• Czech Republic
• France
• Germany
• Italy
• Netherlands
• Poland
• Spain
• United Kingdom
• United States

Links

• nct
• ictrp